Novartis has announced plans to invest $23 billion over five years to expand its pharmaceutical manufacturing footprint across the United States. The company, which develops and produces medicines, is committing to the construction and expansion of 10 U.S.-based facilities, including seven new sites. This investment is expected to create nearly 1,000 new jobs at Novartis and approximately 4,000 additional jobs across the country. 

The expansion includes the establishment of four new manufacturing facilities in yet-to-be-announced states. These will consist of three facilities focused on biologics drug substances, drug products, device assembly, and packaging, and one facility dedicated to chemical drug substances, oral solid dosage forms, and packaging. Novartis will also build two new radioligand therapy (RLT) manufacturing facilities in Florida and Texas and expand three existing RLT sites in Indianapolis, Indiana; Millburn, New Jersey; and Carlsbad, California. 

As part of this plan, Novartis will open a $1.1 billion biomedical research innovation hub in San Diego, California. The complex, expected to open between 2028 and 2029, will provide advanced scientific infrastructure and drug discovery capabilities to support its West Coast research efforts. 

With these investments, Novartis will have manufacturing capacity in the U.S. for all its core technology platforms, including small molecules and biologics. The company will also bring internal manufacturing of its siRNA technology to the U.S. for the first time. The expanded production network will enable Novartis to manufacture 100% of its key medicines domestically, significantly increasing current output levels. 

What people are saying 

In a recent quote, Vas Narasimhan, CEO, Novartis, said, "As a Swiss-based company with a significant presence in the US, these investments will enable us to fully bring our supply chain and key technology platforms into the US to support our strong US growth outlook. These investments also reflect the pro-innovation policy and regulatory environment in the US that supports our ability to find the next medical breakthroughs for patients." 

Investing in American manufacturing in 2025 

This map shows where manufacturers are choosing to invest their resources, whether they are building new production facilities or expanding existing plants.